Albumin Market Size, Share, Growth, and Industry Analysis, By Type (Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin), By Application (Therapeutics, Vaccine Ingredient, Culture Medium Ingredient and Others), and Regional Insights and Forecast to 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

ALBUMIN MARKET OVERVIEW

The global albumin market size was USD 6.15 billion in 2025 and is projected to touch USD 9.76 billion by 2034, exhibiting a CAGR of 6.6% during the forecast period.

Albumin, produced exclusively by the liver, is the most abundant protein in human blood plasma, comprising 50–60% of total plasma proteins. It is also important in the maintenance of the fluid state by oncotic pressure which prevents it from escaping into the tissues as well as in the maintenance of blood pressure, besides the risk of edema. In addition to fluid regulation, albumin is a versatile carrier protein transporting hormones, fatty acids, bilirubin, calcium, various vitamins, enzymes, and drugs and modulating their distribution and their activity. It is easily water-soluble and circulates well, and low levels are an important marker of poor health which can be caused by a liver and kidney problem, nutritional deficiencies or inflammation, and high levels are usually because of dehydration.

Clinically, albumin is a very crucial drug administered in the treatment of low blood volume, poor blood flow, and organ malfunction in cases of shock, liver cirrhosis or damage, and burns. Most commonly used is human serum albumin and bovine serum albumin is also used which is derived from cattle plasma and, recombinant albumin, produced out of recombinant DNA in bacteria or viruses. Besides medicine, albumin is a family of proteins which includes ovalbumin in egg white and lactalbumin in milk. It should be noted that albumin must not be mistaken for albumen or egg white protein. It has flexible functionalities which make it a permanent necessity in healthcare and allow it to be used as an excellent biomarker of organ health.

COVID-19 IMPACT

Pandemic disruptions strained supply, raised doubts and negatively affected the market

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

Pandemic disruptions during COVID-19 negatively impacted the global albumin market despite its therapeutic potential. The incredible increase in demand made to supply the much-needed albumin to treat sick patients, and especially those experiencing severe respiratory distress, and put strain on supply channels and caused shortages across the globe. Lockdowns, transport restrictions and lower manufacturing capacity hindered production and distribution, causing non-COVID treatments such as liver failure, trauma and burns to be delayed. Moreover, the variability in clinical responses and lack of a universal algorithm of albumin administration in patients started to question the drug efficacy too, which subdued the level of confidence among healthcare professionals in albumin efficacy and provoked additional barriers to market development.

LATEST TRENDS

Growing applications in regenerative medicine to drive the market

Growing applications of albumin in regenerative medicine are driving advancements in tissue engineering and wound healing. Due to these distinct characteristics, biocompatible, non-immunogenic, and the affinity to bind and carry bioactive molecules, it is a ground-breaking biomaterial, which can be utilised in the medical field. Such sequentially fabricated inorganic scaffolds are found to be useful in tissue engineering as albumin-based scaffolds not only facilitate cell adhesion, proliferation, and differentiation, but also allow a tissue with limited function to be replaced by a functional one. In wound healing, albumin increases moisture, decreases oxidative stress and accelerates tissue healing through the provision of vital nutrients and growth factors to the wound. Such advantages make albumin an asset in new and emerging therapies that may be much more valuable than its traditional therapeutic uses.

•   
•   
  

  Request a Free sample to learn more about this report

    

ALBUMIN MARKET SEGMENTATION

By Type

Based on type, the global market can be categorized into Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin

• Human Serum Albumin: Human Serum Albumin is the most common protein in the blood plasma of humans and it is synthesised by a functional liver. It supplies osmotic pressure and maintains the correct fluid balance between the blood vessels and tissues. HSA also serves as a carrier protein that transports drugs, fatty acids and hormones in the body. Clinically, it is a marker that is important in the examination of the liver, kidney, and nutrition. In therapy, HSA is commonly used to treat loss of blood volume and hypoalbuminemia.

• Bovine Serum Albumin: Bovine Serum Albumin is a protein derived from cow blood plasma, widely used in biomedical research. It is a close analogue to human serum albumin, thus an attractive model protein in a research setting. BSA works to stabilise extracellular fluid and to transport small molecules that include steroids and fatty acids. It is used as a blocking agent in immunohistochemistry, a stabilizer in cell cultures, and a protein standard in tests. BSA is non-toxic and non-antigenic, which is being employed so much in connection with drug development, protein purification, and vaccine production.

• Recombinant Albumin: Recombinant Albumin is designed by yeast or bacterial genetic engineering, further assuring a secure and consistent source. It does not require human or animal plasma, which restricts contamination and disease transmission. The type finds extensive application in pharmaceuticals and cell culture media, and is a treatment agent. It can effectively serve as an alternative to patients who are allergic or have complications in the aspect of plasma. Technological breakthroughs complement its stability and functionality performance in medical uses.

By Application

Based on application, the global market can be categorized into Therapeutics, Vaccine Ingredient, Culture Medium Ingredient and Others

• Therapeutics: Therapeutics use of albumin is crucial in critical care for managing fluid balance during blood loss, burns, and shock. It raises the level of protein concentration in the blood of patients with malnutrition, kidney malfunction and liver malfunction. In advanced stages of liver disease, albumin treatment has been shown to decrease water retention and maintain blood flow. It improves survival in severe conditions and multiple-organ failure alongside the use of fluids and antibiotics. Also, albumin infusions are used during procedures such as cardio-pulmonary bypass and treatment of pulmonary edema and nephrosis.

• Vaccine Ingredient: Vaccine Ingredient albumin acts as a stabiliser, preserving vaccine effectiveness during storage and transport. It preserves the stability of active components and extends the shelf life of formulations. Albumin, being a carrier protein, can increase vaccine delivery and immune responses in some vaccines. It is also used in diagnostic kits to maintain enzyme activity and guarantee uniform reactions. Moreover, albumin has an effect of facilitating large-scale vaccine manufacturing due to reduced risks of contamination and enhanced reliability in manufacturing.

• Culture Medium Ingredient: Culture Medium Ingredient albumin is essential in cell culture media, supplying proteins needed for cell growth and survival. It helps to adjust osmotic pressure and transport nutrients to achieve the best cellular performance. Albumin is also used to stabilise growth factors and other essential molecules in research laboratories. It is commonly used in cell growth in diagnostics, research, and the production of biologics. Albumin supplements cell growth is important in the applications of tissue culture and regenerative medicine.

• Others: Others use albumin as a standard protein in biochemical and diagnostic assays. It is a scavenging antioxidant and a healing agent that aids in tissue repair. Albumin helps in drug transport, as it transports drug therapeutics and enhances their distribution. It is also used in biosensors, analysis tools and corrosion protection in the industry. Its flexibility aspect covers the biotechnology and pharmaceutical sectors, where it is used in several applications, at a specialised level.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Rising chronic disease incidence to boost the market

Rising chronic disease incidence is driving increased demand for albumin market growth. Liver cirrhosis, chronic kidney disease and renal failure are also some of the conditions that may have caused the patients to have critically low levels of serum albumin. This shortage may lead to fluid irregularity, edema, trailed drug cargo, and adverse fitness, so albumin treatment must be provided to normalise plasma-protein and support organ performance. The number of people affected by these chronic conditions increases due to ageing populations and lifestyle-related health issues, making the therapeutic albumin demand to increase. The albumin market is therefore expanding worldwide due to the surging demand in clinical applications and the rising burden of chronic conditions.

Increasing surgical volumes to expand the market

Increasing surgical volumes, particularly of complex procedures, are driving greater use of albumin in perioperative care. In surgeries including cardiopulmonary bypass, major trauma surgery and extended abdominal or liver surgery, patients are probably to undergo severe blood loss and fluid volume. In this case, albumin replenishment infusions are imperative during rehydration and will help to preserve the quantity of proteins in the body, renew oncotic pressure, and keep blood circulation normal. The use of this medication prevents the occurrence of edema and enhances tissue perfusion, which is a reason why clinicians prefer to use it. The increasing trends in complex surgery cases performed across the world, due to the rising healthcare infrastructure and patients, a positive factors that are expanding the market significantly.

Restraining Factor

High cost of therapy poses a significant barrier to the market

The high cost of albumin therapy poses a significant barrier to its widespread use in clinical settings. Albumin solutions are significantly more costly than the crystalloid alternatives, which are not as accessible, particularly in the low- and middle-income areas. Such a cost burden can strain the budgets of the healthcare institutions, causing them to either restrict or collect them for those patients who can get maximum benefit, such as severely hypoalbuminemic patients, seriously burned, and critically ill surgical patients. Moreover, albumin therapy is costly and may deter its adoption in standard practice because of its high costs, even though its clinical improvements are well-documented. The financial challenge remains a major drawback, constraining market growth and patient access to this essential protein therapy.

Commercialization of recombinant therapies creates an opportunity for the market

Opportunity

The commercial availability of recombinant albumin can be seen as a step forward in the protein therapy marketplace by decreasing reliance on human and animal blood donors. Whilst manufacturing albumin by using genetically engineered cells, either bacteria, yeast, or mammalian cells, manufacturers produce a consistent, scalable and safer product alternative to plasma-based products. The commercial availability of recombinant albumin can be seen as a step forward in the protein therapy marketplace by decreasing reliance on human and animal blood donors.

Whilst manufacturing albumin by using genetically engineered cells, either bacteria, yeast, or mammalian cells, manufacturers produce a consistent, scalable and safer product alternative to plasma-based products. This method alleviates supply constraints as it reduces the chances of infection, contamination and disease associated with donor-based albumin. Despite its promises, the recombinant albumin development entails a lot of costs and regulatory issues, as well as complex manufacturing, which can hamper adoption. Nevertheless, innovation, expansion of therapeutic applications and a shift in the global albumin market are probably to plummet as a result of the commercialization bid.

Competition from biosimilars and recombinant proteins to challenging the market

Challenge

Competition from biosimilars and recombinant protein products is exerting significant pressure on the traditional albumin market. The pricing pressure builds as more manufacturers come to market with the lab-grown or alternative formulations of albumin, which would erode the profit margins of established plasma-derived albumin vendors. The market could also face market fragmentation as a result of the availability of biosimilars, where the providers in healthcare choose to treat even in critical care cases at lower prices.

This competitive landscape leads to confusion in the minds of investors and manufacturers which hinders the development of new products and innovation. Moreover, fierce pricing policies by biosimilar manufacturers may not allow conventional albuminogen products to preserve market share, negatively affecting general revenues.

•   
•   
  Request a Free sample to learn more about this report

    

ALBUMIN MARKET REGIONAL INSIGHTS

• North America

North America dominates the global albumin market share, with the United States albumin market leading, because of its well-established healthcare industry, biopharmaceutical industry and research and development activities. Albumin and other related products can have high demand due to the high prevalence of chronic diseases, such as liver diseases, kidney disorders and hypovolemia, as well as the presence of the ageing population who need surgical care and conditions that lead to traumatic and surgical-related needs. Comprehensive plasma collection systems, well-developed fractionation factories, and favourable regulatory environments enable the wide application of therapeutic and research-grade albumin. Pharmaceutical investments and innovations in the recombinant albumin technologies also contribute to signifying and furthering its position in the market as the leader, guaranteeing that the market will not decline and the North American market maintains its market share.

• Europe

Europe has the second-largest industry market share of albumin, with a well-developed healthcare system, and an advanced regulatory environment, and a lot of investment in biopharmaceutical research activities. Increased demand is stimulated by a growing ageing population and results in an increasing incidence of chronic conditions needing albumin products as a therapeutic agent. There is also expanding research, cell culture and vaccine production. The government policies and innovation in albumin production make Europe a stronger marketer in the process.

• Asia

Asia-Pacific is developing one of the most promising markets for albumin as healthcare infrastructures have improved and awareness has increased albumin therapy market. Demand is high due to the high population distribution of liver and kidney patients, in addition to rising consumption of biopharmaceuticals. It is facilitated by local production, strategic alliances, governmental support of plasma donations, and recombinant albumin technologies. The continuous innovation and investment in life sciences further boost accessibility and market development in the region.

KEY INDUSTRY PLAYERS

Key industry players are forming strategic partnerships with leading pharmaceutical and biotechnology companies for market expansion

Key industry players in the albumin market are strategically entering partnerships with other pharmaceutical and biotechnology companies in an effort aimed at establishing themselves in the albumin market worldwide. The business alliances allow access to superior research resources, new technologies, and extended distribution channels which will be used in the pursuit of new albumin-based therapeutics and applications. Partnerships are also useful to streamline the manufacturing process, streamline the supply chain, and guarantee stable product levels in clinical and research applications. By linking with the key marketers of this industry, companies can promote faster commercialisation of recombinant and plasma-derived albumin products, satisfy the growing demand in the therapeutic, diagnostic, and biopharmaceutical sectors, as well as strengthen their competitive advantage in a dynamic industry.

List Of Top Albumin Companies

• CSL (Australia)
• Grifols (Spain)
• Shire (Baxalta) (U.S./ Ireland)
• Octapharma (Switzerland)
• Hualan Bio (China)
• CBPO (China)
• RAAS (China)
• Kedrion (Italy)
• Merck (Germany)
• LFB Group (France)
• Albumedix (U.K.)
• Thermo Fisher Scientific (U.S.)

KEY INDUSTRY DEVELOPMENT

April 2025: Gifols is collaborating with IBL International to work on more next-generation biomarker panels based on multiplexed single molecule counting technology. The partnership is in the neurological and oncological direction and other fields and allows improving precision, efficiency, early diagnosis of diseases. The potential of this partnership lies in the possibility of lighter clinical diagnosis, enhanced laboratory economics, and the presence of new solutions around the world by combining automation by Grifols and the skills of IBL in assay development.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

Albumin market players are increasingly focusing on strategic partnerships with pharmaceutical and biotechnology companies to strengthen their global presence and expand applications. These collaborations provide access to advanced research capabilities, innovative technologies, and broader distribution networks, enabling the development of novel albumin-based therapeutics and biopharmaceutical solutions. Partnerships also enhance manufacturing efficiency, optimize supply chains, and ensure consistent product availability across clinical and research uses. By leveraging combined expertise, industry leaders accelerate the commercialization of both recombinant and plasma-derived albumin, meet growing demand in therapeutics, diagnostics, and vaccine production, and secure a competitive edge in an evolving, highly dynamic market landscape.